康希諾(06185.HK)午後升幅曾擴至11% 共同研發鼻噴霧式吸入型新冠疫苗正申請緊急使用
康希諾生物-B(06185.HK)共同研發鼻噴霧式/吸入型新冠疫苗正在申請緊急使用,該股逆市兩連升,繼今早反覆升破20天及10天線後,下午升幅曾擴至11%高見355元,現造347.2元,續升8.5%,成交240萬股,涉資8.14億元。
據內媒上周報道,中國工程院院士陳薇出席浦江一個論壇時表示,新冠疫苗既可透過皮下注射,還可透過鼻噴霧式吸入,後者所需劑量是前者五分一,而且可以形成黏膜免疫。這款由陳薇團隊與康希諾生物共同研發鼻噴霧式/吸入型新冠病毒疫苗正在申請緊急使用。此外,康希諾董事長寧學峰上周於青島一次會議上也透露,康希諾鼻噴霧式/吸入型新冠疫苗現已進入臨床二期試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.